دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Issue Highlights page
doi : 10.1016/S0360-3016(22)03242-4
Volume 114, Issue 4, 15 November 2022, Pages A11-A13
The Oligometastatic State: Balancing Between Cure and Palliation
Salma K.JabbourMD*Sue S.YomMD, PhDâ€
Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?
Rachel M.GlicksmanMD, MSc*David A.PalmaMD, PhD†Matthew P.DeekMD‡C JillianTsaiMD, PhD§SteveChmuraMD, PhD║ShankarSivaMD, MBBS, FRANZCR¶PietOstMD, PhD#Phuoc T.TranPhD, MD��AlejandroBerlinMD, MSc††‡‡§§
One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer
Chelain R.GoodmanMD, PhD*Jonathan B.StraussMD, MBAâ€
Aggressive Local Control of Oligorecurrence After Oligometastasis: A Tale of Competing Risk Management
Oluwadamilola T.OladeruMD, MA, MBADivyaYerramilliMD, MBE
The Best Defense is a Good Offense
Cristina M.DeCesarisMDKristineKokenyMD
Stage IV or Locally Advanced Disease?
Melissa PulferMitchellMD, PhD
From Idea to Clinical Practice: A Brief History of Oligometastatic Disease
Phuoc T.TranMD, PhD*PhilipSuteraMD†Ryan M.PhillipsMD, PhD‡Matthew P.DeekMD§StevenChmuraMD, PhD║
Beyond the Visible Spectrum: Considering the Oligometastatic Hypothesis in the Light of a New Era
William TylerTurchanMDSean P.PitrodaMDRalph R.WeichselbaumMD
Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature
DaanNevensPhD*AurélienJongenMD†IsabelleKindtsPhD‡CharlotteBillietPhD*PieterDeseynePhD§║InesJoyePhD*YolandeLievensPhD§║MatthiasGuckenbergerMDâ€
Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study
Sebastian M.ChristMD, PhD*KasparPohlMS†Urs J.MuehlematterMD‡PhilipHeesenMS†AnjaKühnisMSc*JonasWillmannMD*MaiwandAhmadseiMD*Eugenia VlaskouBadraMD*Stephanie G.C.KroezeMD PhD*MichaelMayingerMD*NicolausAndratschkeMD*MartinHuellnerMD‡MatthiasGuckenbergerMD*
Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms
Hyunsoo JoshuaNoMD, CMD*NeelufarRajaBS*RieVon EybenMS*MillieDasMD†MohanaRoyMD†NathanielMyallMD, MS†JoelNealMD, PhD†HeatherWakeleeMD†AlexanderChinMD, MBA*MaximilianDiehnMD, PhD*Billy WisemanLooMD, PhD*Daniel TandelChangMD*Erqi LiuPollomMD, MS*Lucas KasVitzthumMD, MAS*
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
StephenHarrowMBChB, PhD*David A.PalmaMD, PhD†RobertOlsonMD, MSc‡StewartGaedePhD†Alexander V.LouieMD, PhD†§CornelisHaasbeekMD, PhD║LiamMulroyMD¶MichaelLockMD†George B.RodriguesMD, PhD†Brian P.YaremkoMD, MSc, PEng†DevinSchellenbergMD#BelalAhmadMD†SashendraSenthiMD, PhD��AnandSwaminathMD††NeilKopekMD‡‡MitchellLiuMD§§RoelSchlijperMD‡Glenn S.BaumanMD†…SureshSenanMBBS, PhD║
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial
SarahBakerMD, PhD�†WillJiangMD�†BenjaminMouMD�‡Chad R.LundMD�†MitchellLiuMD, CM�§Alanah M.BergmanPhD§DevinSchellenbergMD�†Abraham S.AlexanderMD�║HannahCarolanMD�§SiavashAtrchianMD�‡NickChngPhD¶QuinnMatthewsPhD¶GregoryArbourMSc*AlexanderBennyBSc�ScottTyldesleyMD�§Robert A.OlsonMD, MSc�¶
Real-world Use of Radiation for Newly Diagnosed Brain Metastases in Patients With ALK-positive Lung Cancer Receiving First-line ALK Inhibitor
SameeraKumarMD*XiaoliangWangPhD, MPH†HarlanPittellPhD†Gregory S.CalipPharmD, MPH, PhD†‡Stephanie E.WeissMD*Joshua E.MeyerMD*Trevor J.RoyceMD, MS, MPH†§
Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
YajingWuMD*VivekVermaMD†FeiLiangMD‡QiangLinMD§ZhiguoZhouMD*ZhiyuWangMDâ•‘YiWangMD*JunWangMD*Joe Y.ChangMDPhDâ€
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy
Mark C.KorpicsMD�Rohan R.KatipallyMD�JulienPartouchePhD�DanCutrightPhD�Kelli B.PointerMD, PhD�Christine M.BestvinaMD�Jason J.LukeMD†Sean P.PitrodaMD�James J.DignamPhD‡Steven J.ChmuraMD, PhD�AdityaJulooriMD�
Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study
RodolfoChicas-SettMD, MSc, PhD*†‡JuanZafraMD, MSc*‡§║¶DelvysRodriguez-AbreuMD, PhD#JuanCastilla-MartinezMD, MSc*��GretelBenitezMD¶BarbaraSalasMD, PhD*SamuelHernandezMD††MartaLloretMD, PhD*Juan LuisOnievaMSc‡§¶‡‡IsabelBarraganPhD‡§¶‡‡§§Pedro C.LaraMD, PhD║║¶¶
Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade
UmairMahmoodMSc*Mai AnhHuynhMD, PhD*Joseph H.KilloranPhD*Jack M.QianMD*Eric H.BentMD, PhD*Ayal A.AizerMD, MHS*Raymond H.MakMD*Harvey J.MamonMD, PhD*Tracy A.BalboniMD, MPH*LaurenGunastiBA*Patrick A.OttMD, PhD†Mark M.AwadMD, PhD‡Jonathan D.SchoenfeldMD, MPhil, MPH*
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials
HansKimMD*Bhanu P.VenkatesuluMD†Matthew T.McMillanMD‡VivekVermaMD§Steven H.LinMD, PhD§Joe Y.ChangMD§James W.WelshMD§
Radiation Therapy in Oligometastatic Prostate Cancer
SivenChinniahMD�BradleyStishMD†Brian A.CostelloMD‡LancePagliaroMD‡DanielChildsMD‡FernandoQuevedoMD‡FabriceLucienPhD§AlanBryceMD║Sean S.ParkMD, PhD†Jacob J.OrmeMD, PhD‡
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
Rachel M.GlicksmanMD, MSc�†MatthewRamotarHBSc†UrMetserMD‡Peter W.ChungMD�†ZhihuiLiuPhD§¶DouglassVinesMRT(N)-PET�†AntonioFinelliMD, MSc#RobertHamiltonMD, MPH#Neil E.FleshnerMD, MPH#NathanPerlisMD, MSc#Alexandre R.ZlottaMD, PhD#AndrewBayleyMD�†JoelleHelouMD, MSc�†SrinivasRamanMD�†GirishKulkarniMD, PhD#CharlesCattonMD�†TonyLamBSc†RosannaChanMRT(N)-MR‡…AlejandroBerlinMD MSc*†��
Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation
ClaireHaoBS*ColtonLadburyMD*YungLyouMD, PhD†SaroManoukianMD‡ChristopherRuelMS§PaulFrankelPhD§TanyaDorffMD†JeffreyWongMD*SumantaPalMD†PrzemyslawTwardowskiMD║SavitaDandapaniMD, PhD*
Common Iliac Node-Positive Prostate Cancer Treated With Curative Radiation Therapy: N1 or M1a?
PradnyaChopadeMD�PriyamvadaMaitreMD�SamDavidMBBS�GitanjaliPanigrahiMSc�PallaviSinghMSc�ReenaPhurailatpamMSc†VedangMurthyMD�
Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Benjamin J.RichMD*ChrisMontoyaMD*William H.JinMD*Benjamin O.SpielerMD*Brandon A.MahalMD*RodrigoDelgadilloPhD*MarijoBilusicMD, PhD†Matthew C.AbramowitzMD*AlanPollackMD, PhD*AlanDal PraMD�
Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity
FabriceLucienPhD�†YohanKimPhD*JingQianPhD‡Jacob J.OrmeMD, PhD§HenanZhangMD†AliArafaMD*FevenAbrahaMS║IshworThapaMS¶Erik J.TryggestadPhD‡William S.HarmsenPhD║JorgenaKostiMD*HeshamAliPhD¶Val J.LoweMD#Geoff B.JohnsonMD#Eugene D.KwonMD*†HaidongDongMD, PhD*†Sean S.ParkMD, PhD‡
Stereotactic Body Radiation Therapy for Metastases in Long Bones
IndiraMadaniMD, PhD*ArjunSahgalMD†DarbyErlerMRT(T), MHSc†Bradley J.StishMD‡Kenneth R.OlivierMD‡Sean S.ParkMD, PhD‡W.S.C.EppingaMD§EnricaSeravalliPhD§Kristin J.RedmondMD, MPH║YilinCaoMD║ShankarSivaMBBS, PhD#DavidChang#Timothy K.NguyenMD��MelissaO'NeilMRT(T)��MatthiasGuckenbergerMD*
Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy
Maria C.ThomasMD�†Yu-HuiChenPhD‡ElliotFiteBA*AndrewPangilinanBA*KaterinaBubeloBA*AlexanderSpektorMD, PhD*Tracy A.BalboniMD, MPH*Mai AnhHuynhMD, PhD*
Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study
PierinaNavarriaMD*DavideBaldacciniMD*ElenaClericiMD*BeatriceMariniMD*LucaCozziPhD*DavideFranceschiniMD*Alexia FrancescaBertuzziMD‡VittorioQuagliuoloMD§ValterTorriMDâ•‘PiergiuseppeColomboMD¶CiroFranzeseMD*†LuisaBelluMD*MartaScorsettiMD*â€
Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma
Paulina M.GutkinBS*Rievon EybenMS†AlexanderChinMD, MBA†Sarah S.DonaldsonMD†JustinOhMD†AliceJiangBS†Kristen N.GanjooMD‡Raffi S.AvedianMD§MatÃasBruzoniMDâ•‘Robert J.SteffnerMD§Everett J.ModingMD, PhD†Susan M.HinikerMDâ€
A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer
Krishan R.JethwaMD*ZhaohuiJinMD†Christopher L.HallemeierMD*
Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes
Ahmed M.ElamirMD*John D.KaralisMD†Nina NiuSanfordMD*Patricio M.PolancoMD†Michael R.FolkertMD, PhD‡Matthew R.PorembkaMD†Syed AliKazmiMD§RavikanthMaddipatiMD§Herbert J.ZehMD†Robert D.TimmermanMD*SongZhangPhD║MatteoLigorioMD, PhD†Muhammad ShaalanBegMD§Todd A.AguileraMD, PhD*
Oligometastasis in Head and Neck Squamous Cell Carcinoma
Dominic H.MoonMDDavid J.SherMD, MPH
Salvage (Re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer
SupriyaChopraMD, DNB�BabushaKalraDMRT, DNB†JaahidMulaniMD*JeevanshuJainMSc*LavanyaGurramMD†PrachiMittalMD†MitaliAloneMSc‡JayaGhoshDM§SushmitaRathDM§SeemaGuliaDM§SudeepGuptaDM§
